StoryCommercial
Oral Wegovy surpasses 3 million prescriptions in five months following January 2026 launch
Novo Nordisk's oral Wegovy (semaglutide 25 mg once daily) surpassed 3 million prescriptions filled by June 2026, approximately five months after the January 2026 market launch. This rapid uptake demonstrates strong patient demand for an oral GLP-1 option.
- Roughly 1 prescription filled every 5 seconds at peak adoption, reflecting accelerated obesity treatment initiation across primary care and specialist settings.
- Reached 1 million prescriptions in 12 weeks (by March 23, 2026) and accumulated 2 million additional prescriptions in the following 10 weeks.
- More than 80% of new prescriptions went to patients new to GLP-1 therapy, indicating the oral form expands the market rather than cannibalizing injections.
- Medicare access began July 1, 2026, with a $50 monthly copay for eligible beneficiaries.